Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations von Dankner, Matthew, Rose, April A. N., Rajkumar, Shivshankari, Siegel, Peter M., Watson, Ian R.

Volltext

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties von Rose, April A N, Annis, Matthew G, Dong, Zhifeng, Pepin, Francois, Hallett, Michael, Park, Morag, Siegel, Peter M

Volltext

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis von Rose, April A. N., Elser, Christine, Ennis, Marguerite, Goodwin, Pamela J.

Volltext

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies von Riaud, Melody, Maxwell, Jennifer, Soria-Bretones, Isabel, Dankner, Matthew, Li, Meredith, Rose, April A. N.

Volltext

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer von Rose, April A N, Biondini, Marco, Curiel, Rafael, Siegel, Peter M

Volltext

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases von Tabariès, Sébastien, Ouellet, Véronique, Hsu, Brian E, Annis, Matthew G, Rose, April A N, Meunier, Liliane, Carmona, Euridice, Tam, Christine E, Mes-Masson, Anne-Marie, Siegel, Peter M

Volltext

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas von Dankner, Matthew, Lajoie, Mathieu, Moldoveanu, Dan, Nguyen, Tan-Trieu, Savage, Paul, Rajkumar, Shivshankari, Huang, Xiu, Lvova, Maria, Protopopov, Alexei, Vuzman, Dana, Hogg, David, Park, Morag, Guiot, Marie-Christine, Petrecca, Kevin, Mihalcioiu, Catalin, Watson, Ian R, Siegel, Peter M, Rose, April A N

Volltext

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB von Rose, April A N, Annis, Matthew G, Frederick, Dennie T, Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R, Flaherty, Keith T, Siegel, Peter M

Volltext

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer von ROSE, April A. N, GROSSET, Andrée-Anne, GABOURY, Louis, SIEGEL, Peter M, ZHIFENG DONG, RUSSO, Caterina, MACDONALD, Patricia A, BERTOS, Nicholas R, ST-PIERRE, Yves, SIMANTOV, Ronit, HALLETT, Michael, PARK, Morag

Volltext

Overexpression of Galectin-7, A Myoepithelial Cell Marker, Enhances Spontaneous Metastasis of Breast Cancer Cells von Demers, Mélanie, Rose, April A.N, Grosset, Andrée-Anne, Biron-Pain, Katherine, Gaboury, Louis, Siegel, Peter M, St-Pierre, Yves

Volltext

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer von Bendell, Johanna, Saleh, Mansoor, Rose, April A N, Siegel, Peter M, Hart, Lowell, Sirpal, Surendra, Jones, Suzanne, Green, Jennifer, Crowley, Elizabeth, Simantov, Ronit, Keler, Tibor, Davis, Thomas, Vahdat, Linda

Volltext

Individual Differences in Trust in Autonomous Robots: Implications for Transparency von Matthews, Gerald, Lin, Jinchao, Panganiban, April Rose, Long, Michael D.

Volltext

How can we integrate the biology of breast cancer cell dormancy into clinical practice? von Elkholi, Islam E., Rose, April A.N., Aguirre-Ghiso, Julio A., Côté, Jean-François

Volltext

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer von Maric, Gordana, Rose, April An, Annis, Matthew G, Siegel, Peter M

Volltext

BRAF Mutation Class and Clinical Outcomes-Letter von Dankner, Matthew, Rose, April A N

Volltext

The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers von Kazandjian, Suzanne, Rousselle, Emmanuelle, Dankner, Matthew, Cescon, David W, Spreafico, Anna, Ma, Kim, Kavan, Petr, Batist, Gerald, Rose, April A N

Volltext

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer von Dankner, Matthew, Maxwell, Jennifer, Rose, April A. N.

Volltext

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin von Biondini, Marco, Kiepas, Alex, El-Houjeiri, Leeanna, Annis, Matthew G., Hsu, Brian E., Fortier, Anne-Marie, Morin, Geneviève, Martina, José A., Sirois, Isabelle, Aguilar-Mahecha, Adriana, Gruosso, Tina, McGuirk, Shawn, Rose, April A. N., Tokat, Unal M., Johnson, Radia M., Sahin, Ozgur, Bareke, Eric, St-Pierre, Julie, Park, Morag, Basik, Mark, Majewski, Jacek, Puertollano, Rosa, Pause, Arnim, Huang, Sidong, Keler, Tibor, Siegel, Peter M.

Volltext

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorecta... von Dankner, Matthew, Rose, April A. N.

Volltext

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy von Rajkumar, Shivshankari, Berry, Diana, Heney, Kayla A., Strong, Colton, Ramsay, LeeAnn, Lajoie, Mathieu, Alkallas, Rached, Nguyen, Tan-Trieu, Thomson, Cameron, Ahanfeshar-Adams, Mozhdeh, Dankner, Matthew, Petrella, Teresa, Rose, April A.N., Siegel, Peter M., Watson, Ian R.

Volltext